|
1）Ziemin-van der Poel S, McCabe NR, Gill HJ, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A. 1991; 88: 10735-9
|
|
|
|
2）Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell. 1992; 71: 691-700
|
|
|
|
|
|
3）Patel A, Dharmarajan V, Vought VE, et al. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex. J Biol Chem. 2009; 284: 24242-56
|
|
|
|
|
|
4）Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell. 2002; 10: 1107-17
|
|
|
|
|
|
5）Hess JL. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med. 2004; 10: 500-7
|
|
|
|
|
|
6）Min J, Feng Q, Li Z, et al. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell. 2003; 112: 711-23
|
|
|
|
|
|
7）Frederiks F, Tzouros M, Oudgenoeg G, et al. Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states. Nat Struct Mol Biol. 2008; 15: 550-7
|
|
|
|
|
|
8）Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell. 2005; 121: 167-78
|
|
|
|
|
|
9）Mueller D, Bach C, Zeisig D, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood. 2007; 110: 4445-54
|
|
|
|
|
|
10）Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007; 7: 823-33
|
|
|
|
|
|
11）Chang MJ, Wu H, Achille NJ, et al. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 2010; 70: 10234-42
|
|
|
|
|
|
12）Jo SY, Granowicz EM, Maillard I, et al. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood. 2011; 117: 4759-68
|
|
|
|
|
|
13）Nguyen AT, Taranova O, He J, et al. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood. 2011; 117: 6912-22
|
|
|
|
|
|
14）Bernt KM, Zhu N, Sinha AU, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011; 20: 66-78
|
|
|
|
|
|
15）Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013; 122: 1017-25
|
|
|
|
|
|
16）Yu W, Chory EJ, Wernimont AK, et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun. 2012; 3: 1288
|
|
|
|
|
|
17）Stein EM, Garcia-Manero G, Rizzieri DA, et al. The DOT1L inhibitor EPZ-5676: safety and activity in relapsed/refractory patients with MLL-rearranged leukemia. Blood. 2014; 124: Abstract 387
|
|
|
|
|